| 期 |
栏目 |
标题 |
文件 |
| 编号 8 (2016) |
Articles |
COMBINATION OF VEMURAFENIB+KOBIMETINIB FUNDAMENTALLY CHANGES PROGNOSIS FOR METASTATIC MELANOMA |
|
| 编号 17 (2016) |
Articles |
ROLE OF NEW ANTIANGIOGENIC DRUGS IN THE SECOND-LINE TREATMENT OF NON-SMALL-CELL LUNG CANCER |
|
| 编号 7 (2018) |
Articles |
PRINCIPLES OF MODERN IMMUNOTHERAPY |
|
| 卷 26, 编号 7 (2019) |
Articles |
Prognostic markers for testicular germ cell tumors. Research perspectives |
|
| 卷 26, 编号 7 (2019) |
Articles |
Modern immunotherapy for kidney cancer |
|
| 卷 26, 编号 7 (2019) |
Articles |
PEComas: what are the treatment options? Literature review and personal experience |
|
| 卷 27, 编号 7 (2020) |
Articles |
Comparison of systems for evaluating the effectiveness of modern immunotherapy |
|
| 卷 27, 编号 11 (2020) |
Articles |
Ten-year experience of pharmacotherapy for soft tissue sarcomas |
|
| 卷 27, 编号 11 (2020) |
Articles |
The use of panitumumab in the treatment of chemoresistant metastatic sigmoid colon adenocarcinoma: a clinical case |
|
| 卷 28, 编号 7 (2021) |
Articles |
Experience of using prolgolimab in real clinical practice |
|
| 卷 28, 编号 7 (2021) |
Articles |
Immunological aspects of metronomic chemotherapy regimens |
|
| 卷 28, 编号 7 (2021) |
Articles |
Assessment of the dynamics of immunological parameters at the beginning of therapy as prognostic and predictive factors in patients with melanoma |
|
| 卷 28, 编号 11 (2021) |
Articles |
Neoadjuvant immunotherapy for non-small cell lung cancer |
|
| 卷 29, 编号 7 (2022) |
Articles |
The use of pazopanib in the treatment of disseminated soft tissue sarcoma: personal experience |
|
| 卷 29, 编号 11/12 (2022) |
Articles |
Possibilities of the combination of avelumab and axitinib in the first line in patients with advanced renal cell carcinoma |
|
